A Phase 3 interventional study of Lung ultrasound in Chronic Heart Failure, Lung; Congestive and Acute Decompensated Heart Failure, sponsored by IRCCS San Raffaele. Terminated at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-08-25.
Sponsored by IRCCS San Raffaele · Phase 3, Interventional, and Treatment
Purpose. The aim of this study is to evaluate whether lung ultrasound, in addition to physical examination, leads to a reduction of the admission rate for acute decompensated heart failure of patients with chronic heart failure (HF) followed in the outpatients heart failure clinic.
Methods. This is a prospective randomized study. The planned sample size consists of 440 patients with chronic HF.
The inclusion criteria are: (1) male and female aged between 18 and 90 years (2) signed written informed consent (3) history of HF for at least six months, (4) left ventricular ejection fraction \< 45%, (5) adequate medical therapy for HF for at least two months.
The exclusion criteria are: (1) concomitant enrollment in other clinical studies, or treatment with experimental drugs or devices within 30 days of clinical assessment, (2) inability to undergo to the planned follow-up and procedures (3) documented pulmonary infections (3) interstitial lung disease and class 4 chronic obstructive pulmonary disease according to GOLD classification.
Patients are randomized in two groups: group A, patients undergoing to lung ultrasound and physical examination; and group B, patients undergoing to physical examination only. Patients are evaluated at baseline and after three months with medical history, Quality of Life test, physical examination, blood sample for hematochemical (creatinine, electrolytes, BNP/NTpro-BNP).
The diuretic therapy is then optimized according to the presence and severity of B-lines in group A and physical examination in group B.
Only patients enrolled in group A undergo to a lung ultrasound examination to assess the extent of pulmonary congestion, through its evidence of B-lines. B-lines originate from the contrast between air-filled structures and water-thickened pulmonary interlobular septa. This leads to linear echogenic vertical artefacts that spread from the pleural layers downwards in the screen. The ultrasound examination is performed with a handheld echocardiography device. The physician carries out a scan of the pulmonary fields, from basal towards mid and apical fields, through the midaxillary line while the patient lies supine. The quantification of B-lines is performed according to their extent over the lung fields. All the information are recorded in dedicated forms.
The results are evaluated according to the following criteria. The primary end-point is a significant reduction of hospitalizations for acute decompensated HF in group A during the follow-up period. The secondary end-points are changes of NT-proBNP values, quality of life test (QLT) score and cardiac mortality.
(1) male and female aged between 18 and 90 years (2) signed written informed consent (3) history of HF for at least six months, (4) left ventricular ejection fraction \< 45%, (5) adequate medical therapy for HF for at least two months.
Exclusion Criteria:
(1) concomitant enrollment in other clinical studies, or treatment with experimental drugs or devices within 30 days of clinical assessment, (2) inability to undergo to the planned follow-up and procedures (3) documented pulmonary infections (4) interstitial lung disease, class 4 chronic obstructive pulmonary disease according to GOLD guidelines (5) chronic dialysis.
Group A includes patients undergoing lung ultrasound and physical examination.
Diagnostic Test: Lung ultrasound
Group B includes patients undergoing physical examination only.
Diagnostic Test: Lung ultrasound
Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
Reduction of hospitalizations for acute decompensated heart failure
Significant reduction of hospitalizations for acute decompensated heart failure in group A during the 90-day follow-up period.
Time frame: 90 days
Natriuretic peptides values
Significant reduction of natriuretic peptides values in group A during the 90-day follow-up period.
Time frame: 90 days
Quality of life test (QLT) score
Significant reduction of QTL score in group A during the 90-day follow-up period.
Time frame: 90 days
Cardiac mortality
Significant reduction of cardiac mortality rate in group A versus group B.
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS San Raffaele